Axsome Therapeutics to Present at Upcoming Investor Conferences
February 19, 2021 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021
February 16, 2021 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, March 1, 2021 at 8:00 AM Eastern Time NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical...
Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
December 31, 2020 06:15 ET
|
Axsome Therapeutics, Inc.
ACCORD is the second pivotal trial of AXS-05 in Alzheimer’s disease agitation No treatments are currently approved for Alzheimer’s disease agitation NEW YORK, Dec. 31, 2020 (GLOBE...
Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine
December 31, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Over 21,000 migraine attacks treated with AXS-07 Achieved migraine pain relief in approximately 70% of patients, and pain freedom in approximately 40% of patients, at 2 hours Achieved...
Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation
December 08, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
68% reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4 Resolution of suicidal ideation achieved by 60% of patients by Week 1, and 78% by Week 4 Effects consistent with...
Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder
December 01, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Rapid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response), and sustained over 12 months Rapid and substantial improvement in...
Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 05, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
COMET Phase 3 long-term safety trial of AXS-05 in MDD, and MOVEMENT Phase 3 long-term safety trial of AXS-07 in migraine completed NDA submissions for AXS-05 in depression expected in January 2021,...
Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform
November 04, 2020 07:03 ET
|
Axsome Therapeutics, Inc.
Collaboration provides Axsome access to new digital technologies developed by Veeva NEW YORK and PLEASANTON, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics to Present Data from the ADVANCE-1 Trial of AXS-05 in Alzheimer’s Disease Agitation at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 03, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020
October 28, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Thursday, November 5, 2020 at 8:00 AM Eastern Time NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...